Shares in many large drugmakers fell Wednesday on the president's threat, which could further challenge an already battered ...

We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to ...

Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and Zepbound generating billions of dollars in annual sales. The company has ...

Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE), are under pressure on Wednesday after President Trump announced that ...

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

"We’re going to tariff our pharmaceuticals, and once we do that, they’re going to come rushing back into our country because ...

The pharma sector was spared from Trump's sweeping tariff plan last week, which kicked in on Wednesday, but the U.S. president had previously pledged to impose tariff on pharma products and his ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Former top legal executives at large companies including Microsoft, Intel and Eli Lilly submitted a legal brief on Tuesday ...

Fintel reports that on April 8, 2025, Goldman Sachs upgraded their outlook for Eli Lilly and (NYSE:LLY) from Neutral to Buy.

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

We recently published a list of Jim Cramer Nailed These 11 Stock Picks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim ...